AZN vs BCRX

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.

The Advanced Deterministic Scorecard reveals significant concerns with a weak Piotroski F-Score of 2/9, indicating poor financial health, and an absent Altman Z-Score, preventing a clear distress risk assessment. Despite this, the company shows strong revenue growth of 36.1% YoY, improving operating margins, and a bullish analyst consensus of 'strong_buy' with a $20.50 target price. However, negative profit margin, insider selling, and lack of key valuation metrics like Graham Number and Altman Z-Score create substantial uncertainty. The stock trades well below its target, suggesting potential upside, but fundamental weaknesses and mixed earnings performance temper optimism.